重组人血小板生成素、重组人白介素11分别联合糖皮质激素治疗成人原发性免疫性血小板减少症的疗效

doi:10.3969/j.issn.1006-5725.2019.16.024

实用医学杂志 ›› 2019, Vol. 35 ›› Issue (16): 2624-2627.doi: 10.3969/j.issn.1006-5725.2019.16.024

重组人血小板生成素、重组人白介素11分别联合糖皮质激素治疗成人原发性免疫性血小板减少症的疗效

谢坤莹, 魏锦, 邹兴立, 赵攀

川北医学院附属医院血液科（四川南充 637000）

收稿日期:2019-03-19 出版日期:2019-08-27 发布日期:2019-08-27
基金资助:
南充市科学技术项目（编号：NSMC20170412）

Efficacy analysis of recombinant human thrombopoietin or recombinant human interleukin 11 combined with glucocorticoid respectively in treatment of adult primary immune thrombocytopenia

XIE Kunying, WEI Jin, ZOU Xingli, ZHAO Pan

Department of Haematology, the Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, China

Received:2019-03-19 Online:2019-08-27 Published:2019-08-27

摘要/Abstract

摘要： 目的探讨重组人血小板生成素（recombinant human thrombopoietin,rhTPO）、重组人白介素11（recombinant human interleukin 11,rhIL-11）分别联合糖皮质激素在成人原发性免疫性血小板减少症（primary immune thrombocytopenia, ITP）的疗效分析。方法回顾性分析2016年9月至2018年9月川北医学院附属医院收治的80例ITP患者病例资料。据用药情况分为观察组和对照组,观察组使用rhTPO联合甲泼尼龙治疗,对照组使用rhIL-11联合甲泼尼龙治疗。甲泼尼龙1 mg/（kg·d）,rhTPO 15 000 IU/d,rhIL-11 1.5 mg/d,rhTPO、rhIL-11用药疗程均为14 d,若疗程不足14 d,血小板> 100 × 10⁹/L,停用rhTPO、rhIL-11。比较患者完全反应率（CR）,达到CR的时间,治疗前后血小板水平变化,以及不良反应的发生率。结果治疗后观察组CR率与对照组CR率差异无统计学意义（P > 0.05）。治疗后第9天观察组血小板水平高于对照组,差异有统计学意义（P < 0.01）。治疗后第12、15天观察组与对照组血小板水平差异无统计学意义（P > 0.05）。结论 rhTPO联合甲泼尼龙治疗ITP患者较rhIL-11联合甲泼尼龙治疗提升血小板速度更快。

关键词: 重组人血小板生成素, 重组人白介素11, 糖皮质激素, 原发性免疫性血小板减少症

Abstract: Objective To investigate the efficacy of recombinant human thrombopoietin （rhTPO） or recombinant human interleukin 11 （rhIL-11） combined with glucocorticoid respectively in adult primary immune thrombocytopenia（ITP）. Methods A retrospective analysis was performed to review the cases data of 80 adult patients with ITP admitted to the Affiliated Hospital of North Sichuan Medical College from September 2016 to September 2018. According to the usage of the drug, the cases was divided into the observation group and the control group. The observation group was treated with recombinant human thrombopoietin （rhTPO） combined with methylprednisolone, while the control group was treated with recombinant human interleukin-11 （rhIL-11） combined with methylprednisolone. The dosage of methylprednisolone, rhTPO and rhIL-11 were 1 mg/（kg·d）, 15 000 IU/d, 1.5 mg/d respectively. All of the groups were treated for 14 days. If the treatment period was less than 14 days, platelets of the patient were more than 100 × 10⁹/L, the usage of rhTPO and rhIL-11 were stopped. The CR （complete response） rate, the time point that reach to CR, the platelet level before and after treatment, and the incidence of adverse reactions were recorded and compared. Results There was no significant difference in the complete response rate between the observation group and the control group after treatment （P > 0.05）. The platelet level of the observation group was higher than that of the control group on the 9th day after treatment （P < 0.01）. There was no significant difference between the platelet levels of the two groups on the 12th and 15th day（P > 0.05）. Conclusion rhTPO combined with methylprednisolone increased platelet level in the treatment of ITP patients faster than rhIL-11 combined with methylprednisolone.

Key words: recombinant human thrombopoietin, recombinant human interleukin 11, glucocorticoid, primary immune thrombocytopenia

谢坤莹, 魏锦, 邹兴立, 赵攀. 重组人血小板生成素、重组人白介素11分别联合糖皮质激素治疗成人原发性免疫性血小板减少症的疗效[J]. 实用医学杂志, 2019, 35(16): 2624-2627.

XIE Kunying, WEI Jin, ZOU Xingli, ZHAO Pan. Efficacy analysis of recombinant human thrombopoietin or recombinant human interleukin 11 combined with glucocorticoid respectively in treatment of adult primary immune thrombocytopenia[J]. The Journal of Practical Medicine, 2019, 35(16): 2624-2627.

参考文献 18

[1]	ZUFFEREY A, KAPUR R, SEMPLE J.Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP)[J]. J Clin Med, 2017, 6(2): 16.
[2]	侯明,秦平. 成人原发免疫性血小板减少症诊治的中国专家共识(2016版)解读[J]. 临床血液学杂志, 2016, 29(7): 523-527.
[3]	GÓMEZ-ALMAGUER D. Eltrombopag-based combination treatment for immune thrombocytopenia[J]. Ther Adv Hematol, 2018, 9(10): 309-317.
[4]	凌奕文,张复华,赵莹,等. 髓源性抑制细胞在免疫性血小板减少性紫癜中的临床意义[J]. 实用医学杂志,2018,34(15):2552-2555.
[5]	GARABET L, GHANIMA W, HELLUM M, et al.Thrombin-generating capacity of microvesicles (MVs) in patients with immune thrombocytopenia (ITP) before and during treatment with thrombopoietin-receptor agonists (TPO-RA)[J]. Blood,2018,132(Suppl 1):2511.
[6]	AHMED R, DEVASIA A J,VISWABANDYA A, et al.Long-term outcome following splenectomy for chronic and persistent immune thrombocytopenia (ITP) in adults and children[J]. Ann hematol,2016, 95(9): 1429-1434.
[7]	胡兰,喻雕,周泽平,等. 难治性原发免疫性血小板减少症的治疗进展[J]. 实用医学杂志, 2017, 33(3): 337-339.
[8]	WU Q,REN J,WU X,et al.Recombinant human thrombopoietin improves platelet counts and reduces platelet transfusion possibility among patients with severe sepsis and thrombocyto-penia: a prospective study[J]. J Crit Care,2014, 29(3):362-366.
[9]	BAO W,BUSSEL J B,HECK S,et al.Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents[J]. Blood,2010,116(22):4639-4645.
[10]	STAFKEY-MAILEY D, ROY A, LOKHANDWALA T, et al.Evaluation of treatment patterns among patients with newly diagnosed, persistent, and chronic immune thrombocytopenia (ITP) treated with eltrombopag in real world setting in the US[J]. Blood, 2017,130(Suppl 1):2078.
[11]	WANG M, QIN P, ZHOU H, et al.Recombinant human thrombopoietin (rhTPO) and high-dose dexamethasone (HD-DXM) versus high-dose dexamethasone monotherapy as frontline treatment in newly diagnosed adult immune thrombocytopenia (ITP): A prospective, multicentre, randomised, controlled trial[J]. Blood, 2017,130(Suppl 1):13.
[12]	WONG R S M,SALEH M N, KHELIF A, et al. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: Final results of the EXTEND study[J]. Blood, 2017, 130(23): 2527-2536.
[13]	NEUNERT C,DESPOTOVIC J,HALEY K, et al.Thrombopoietin receptor agonist use in children: Data from the pediatric ITP consortium of North America ICON2 study[J]. Pediatr Blood Cancer, 2016, 63(8): 1407-1413.
[14]	MAZZA P,MIONIA C,MELPIGNANO A,et al.The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): A “real life” retrospective multicenter experience of the Rete Ematologica Pugliese (REP)[J]. Ann hematol, 2016, 95(2): 239-244.
[15]	刘新光,刘晓帆,孟月生,等. 重组人血小板生成素联合小剂量利妥昔单抗治疗激素无效/复发成人 ITP 的多中心临床研究[J]. 临床血液学杂志, 2015, 28(5): 778-781.
[16]	HONGLING M A, YONGCHUN H E, LIU Y, et al.Effect of rhIL-11 on Th1/Th2 and T- bet/GATA-3 imbalance in idiopathic thrombocytopenic purpura[J]. Clin Med Chin, 2018, 34(1): 59-63.
[17]	王育丽,唐宇宏,司阳,等. 大剂量地塞米松联合重组人白介素-11 治疗新诊断原发免疫性血小板减少症的观察性研究[J]. 世界临床药物, 2018, 39(1): 19-23.
[18]	LEWIS B J B, LEONTYEV D, NESCHADIM A, et al. GM-CSF and IL-4 are not involved in IVIG-mediated amelioration of ITP in mice: A role for IL-11 cannot be ruled out[J]. Clin Exp Immunol, 2018, 193(3): 293-301.

重组人血小板生成素、重组人白介素11分别联合糖皮质激素治疗成人原发性免疫性血小板减少症的疗效

Efficacy analysis of recombinant human thrombopoietin or recombinant human interleukin 11 combined with glucocorticoid respectively in treatment of adult primary immune thrombocytopenia

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 18

相关文章 1

编辑推荐

Metrics

本文评价